Advertisement

Applied Microbiology and Biotechnology

, Volume 64, Issue 5, pp 618–624 | Cite as

Compactin—a review

  • R. Chakravarti
  • V. SahaiEmail author
Mini-Review

Abstract

Compactin, a hypocholesterolemic molecule, is a competitive inhibitor of 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase, which is a regulatory enzyme for cholesterol biosynthesis. The structural similarity and high affinity of the acid form of compactin and HMG, the natural substrate of enzyme, results in specific and effective inhibition of this enzyme. Inhibition results in reduced levels of mevalonic acid in the body, leading to pleiotropic effects. Various fungi have been used for the commercial production of compactin. Using different strategies for improving production levels, yields have been increased to around 900 times of the amount originally produced. Recently, the gene sequence responsible for compactin production has been cloned and sequenced. This review deals with the chemistry, mode of action, pharmacology, biosynthesis, and production of compactin. A comparative study of various reports dealing with the production of compactin is also included.

Keywords

Lovastatin Compactin Cholesterol Biosynthesis Carbon Catabolite Repression Mevalonic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abe Y, Suzuki T, Ono C, Iwamoto K, Hosobuchi M, Yoshikawa H (2002a) Molecular cloning and characterization of an ML-236B (compactin) biosynthetic gene cluster in Penicillium citrinum. Mol Genet Genomics 267:636–646PubMedGoogle Scholar
  2. Abe Y, Suzuki T, Mizuno T, Ono C, Iwamoto K, Hosobuchi M, Yoshikawa H (2002b) Effects of increased dosage of the ML-236B (compactin) biosynthetic gene cluster on ML-236B production in Penicillium citrinum. Mol Genet Genomics 268:130–137PubMedGoogle Scholar
  3. Albers-Schonberg, Joshou H, Lopez MB (1981) Hypocholesteremic fermentation products and products of preparation. US Patent 4 294 846Google Scholar
  4. Alberts AW (1998) Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62:10J–15JGoogle Scholar
  5. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Mosokowitz MA (2001) Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32:980–986PubMedGoogle Scholar
  6. Askenazi M, Driggers EM, Holtzman DA, Norman TC, Iverson S, Zimmer DP, Boers ME, Blomquist PR, Martinez EJ, Monreal AW, Feibelman TP, Mayorga ME, Maxon ME, Sykes K, Tobin JV, Cordero E, Salama SR, Trueheart J, Royer JC, Madden KT (2003) Integrating transcriptional and metabolite profiles to direct the engineering of lovastatin-producing fungal strains. Nat Biotechnol 21:150–156CrossRefPubMedGoogle Scholar
  7. Bazaraa WA, Hamdy MK, Toledo R (1998) Bioreactor for continuous synthesis of compactin by Penicillium cyclopium. J Ind Microbiol Biotechnol 2:192–202CrossRefGoogle Scholar
  8. Beg ZH, Stonik JA (1982) Reversible inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: reductase kinase and meavlonate kinase are separate enzymes. Biochem Biophys Res Commun 108:559–566PubMedGoogle Scholar
  9. Bowmen L, Geiger E (1984) Optimization of fermentation conditions for alcohol production. Biotechnol Bioeng 26:1492–1497Google Scholar
  10. Brown AG, Smale TC, King J, Hasenkamp R, Thompson RH (1976) Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin 1:1165–1170Google Scholar
  11. Brown MS, Faust JR, Goldstein JL (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in human fibroblasts incubated with compactin (ML-236B), A competitive inhibitor of the reductase. J Biol Chem 253:1121–1128PubMedGoogle Scholar
  12. Byrne GS, Ward OP (1989) Effect of nutrition on pellet formation by Rhizopus arrhizus. Biotechnol Bioeng 33:912–914Google Scholar
  13. Chakravarti R, Sahai V (2002a) A chemically-defined medium for production of compactin by Penicillium citrinum. Biotechnol Lett 24:527–530CrossRefGoogle Scholar
  14. Chakravarti R, Sahai V (2002b) Optimisation of compactin production in chemically defined production medium by Penicillium citrinum using statistical methods. Process Biochem 38:481–486CrossRefGoogle Scholar
  15. Chung KJ, Lee JK, Park JW, Seo DJ, Lee SC (2001) Method for producing pravastatin precursor, ML-236B. US Patent 6 204 032Google Scholar
  16. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F (1999) New insights into the pharmacodynamics and pharmokinetics properties of statins. Pharmacol Theraput 84:413–428CrossRefGoogle Scholar
  17. Davidson MH, Jacobson TA (2001) How statins work: the development of cardiovascular diseases and its treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. www.medscape.com/viewprogram/608Google Scholar
  18. Davignon J, Mabile L (2001) Mechanisms of action of statins and their pleiotropic effects. Ann Endocinol 62:101–112Google Scholar
  19. Davis BL, Cino PM, Szarka L (2000) Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof. US Patent 6 043,064Google Scholar
  20. Demain AL, Kennel YM, Aharonowitz Y (1979) Carbon catabolic regulation of secondary metabolism. Microbial technology: current status, future prospects. Symp Soc Gen Microbiol 29:168–185Google Scholar
  21. Demain AL, Peng Y, Yashphe J, Davis J (1999) Conversion of compactin to pravastatin by Actinomadura. US Patent 5 942 423Google Scholar
  22. Demain AL, Peng Y, Yashphe J, Davis J (2001) Conversion of compactin to pravastatin by Actinomadura. US Patent 6 274 360Google Scholar
  23. Dey G, Mitra A, Banerjee R, Maiti BR (2001) Enhanced production of amylase by optimization of nutritional constituents using response surface methodology. Biochem Eng J 7:227–231CrossRefGoogle Scholar
  24. Endo A (1985) Compactin (ML-236 B) and related compounds as potential cholesterol lowering agents that HMG-CoA reductase. J Med Chem 28:400–405Google Scholar
  25. Endo A, Yamashita H (1985) Microbial phosphorylation of compactin (ML-236B) and related compounds. J Antibiot 38:328–332PubMedGoogle Scholar
  26. Endo A, Kuroda M, Tsujita Y (1976a) ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinum. J Antibiot 29:1346–1348Google Scholar
  27. Endo A, Kuroda M, Tanzawa K (1976b) Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72:323–326Google Scholar
  28. Endo A, Kuroda M, Terahara A, Yoshio T, Chhiro T (1977) Physiologically active substances and fermentative process for producing the same. US Patent 4049495Google Scholar
  29. Endo A, Hasumi K, Negishi S (1985a) Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus rubber. J Antibiot 38:420–423PubMedGoogle Scholar
  30. Endo A, Negishi Y, Iwashita T, Mizukawa K, Hirama M (1985b) Biosynthesis of ML-236B (compactin) and monacolin K. J Antibiot 38:444–448PubMedGoogle Scholar
  31. Endo A, Hasumi K, Yamada A, Shimoda R, Takeshima H (1986) The synthesis of compactin (ML-236B) and monacolin K in fungi. J Antibiot 39:1609–1610PubMedGoogle Scholar
  32. Gallo M, Katz E (1972) Regulation of secondary metabolite biosynthesis: catabolite repression of phenoxazine synthase and actinomycin formation by glucose. J Bacteriol 109:659–667PubMedGoogle Scholar
  33. Galloway P, Greer IA, Sattar N (2002) Statins as novel therapies for osteoporosis. Eur J Obstet Gynecol Reprod Biol 101:4–5CrossRefPubMedGoogle Scholar
  34. George R, Menon AS, Ramasarma T (1980) Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by adenosine derivatives and fatty acylcoenzyme A. Ind J Biochem Biophys 17:1–7Google Scholar
  35. Gerson DF, Xiao X (1995) Process for the production of lovastatin using Coniothyrium fuckelii. US Patent 5 409 820Google Scholar
  36. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharamcol Sci 19:26–37CrossRefGoogle Scholar
  37. Hosobuchi M, Shiori T, Ohyama J, Arai M, Iwado S, Yoshikawa H (1993a) Production of ML-236B, and inhibitor of 3-hydroxy-3-methylglutaryl CoA reductase, by Penicillium citrinum: improvement of strain and culture conditions. Biosci Biotechnol Biochem 57:1414–1419Google Scholar
  38. Hosobuchi M, Ogawa K, Yoshikawa H (1993b) Morphology study in production of ML-236B, a precursor of pravastatin sodium by Penicillium citrinum. J Ferment Bioeng 76:470–475Google Scholar
  39. Hosobuchi M, Fukui F, Matsukawa H, Suzuki T, Yoshikawa H (1993c) Morphology control of preculture during production of pravastatin sodium by Penicillium citrinum. J Ferment Bioeng 76:476–481Google Scholar
  40. Hosobuchi M, Fukui F, Suzuki T, Yoshikawa H (1993d) Fuzzy control in microbial production of ML-236B, a precursor of pravastatin sodium. J Ferment Bioeng 76:482–486Google Scholar
  41. Hutchinson CR, Kennedy J, Park C, Kendrew S, Auclair K, Vederas J (2000) Aspects of the biosynthesis of non-aromatic fungal polyketide by iterative polyketide synthases. Antonie van Leeuwenhoek 78:287–295PubMedGoogle Scholar
  42. Kalil SJ, Maugeri F, Rodrigues MI (2000) Response surface analysis and simulation as a tool for bioprocess design and optimization. Process Biochem 35:539–550Google Scholar
  43. Koizumi J, Mabuchi H, Takeda R (1982) A possible translational control of 3-hydroxy-3-methylglutaryl coenzyme A reductase induction by ML-236B (compactin) in isolated rat hepatocytes. Biochem Biophys Res Commun 108:240–246PubMedGoogle Scholar
  44. Komagata D Yamashita H, Endo A (1986) Microbial conversion of compactin (ML-236B) to ML-236A. J Antibiot 39:1574–1577PubMedGoogle Scholar
  45. Konya A, Jekkel A, Suto J, Salat J (1998) Optimization of compactin fermentation. J Ind Microbiol Biotechnol 20:150–152Google Scholar
  46. Kranjc S, Ivnac I, Schauer M (2002) Biotechnological process for preparing hydroxylated ML-236B derivatives, known as M-4 and M-4′, and analogues thereof. US Patent 6 365 382Google Scholar
  47. Kumar MS, Jana SK, Senthil V, Shasshanka S, Kumar V, Sadhukhan AK (2000) Repeated fed-batch process for improving Lovastatin production. Process Biochem 36:363–368CrossRefGoogle Scholar
  48. Manzoni M, Bergomi S, Rollni M, Cavazzoni V (1999) Production of statins by filamentous fungi. Biotechnol Lett 21:253–257Google Scholar
  49. Martin JF, Revilla G, Zanca DM, Lopez-Nieto MJ (1982) Carbon catabolite regulation of penicillin and cephalosporin biosynthesis. In: Umezawa H et al (eds) Proceedings of symposium Trends in Antibiotic Research. Japan Antibiotic Research Association, Tokyo, pp 258–268Google Scholar
  50. Metz B, Kossen NWF, Van Suizdum JC (1979) The rheology of mould suspensions. Adv Biochem Eng 11:103–156Google Scholar
  51. Miller TL, Wolin MJ (2001) Inhibition of growth of methane-producing bacteria of the ruminant forestomach by hydroxymethylglutaryl-ScoA reductase inhibitors. J Dairy Sci 84:1445–1448PubMedGoogle Scholar
  52. Mok T, Koehler AP, Yu MY, Ellis DH, Johnson PJ, Wickhan NW (1997) Fatal Penicillium citrinum pneumonia with pericarditis in a patient with acute leukemia. J Clin Microbiol 35:2654–2656PubMedGoogle Scholar
  53. Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, Kitahara M, Hamakubo T, Kodama T, Saito Y (2000) Relative induction of mRNA for HMG-CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 7:138–144PubMedGoogle Scholar
  54. Nakanishi M, Goldstein JL, Brown MS (1988) Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 263:8929–8937PubMedGoogle Scholar
  55. Narang S, Sahai V, Bisaria VS (2001) Optimization of xylanase production by Melanocarpus albomyces IIS68 in solid state fermentation using the response surface methodology. J Biosci Bioeng 9:425–427CrossRefGoogle Scholar
  56. Papagianni M, Mattey M, Kristiansen B (1994) Morphology and citric acid production of Aspergillus niger PM1. Biotechnol Lett 9:929–934Google Scholar
  57. Paul GC, Priede MA, Thomas CR (1999) Relationship between morphology and citric acid production in submerged Aspergillus niger fermentation. Biochem Eng J 3:121–129CrossRefGoogle Scholar
  58. Peng Y, Demain AL (1999) A new hydroxylase system in Actinomadura sp. cells converting compactin to pravastatin. J Ind Microbiol Biotechnol 20:373–375Google Scholar
  59. Peng Y, Yashbe J, Demain AL (1997) Biotransformation of compactin to pravastatin by Actinomadura sp. 2966. J Antibiot 52:1032–1035Google Scholar
  60. Plackett RL, Burman JP (1946) The design of optimum multifactorial experiments. Biometrika 33:305–325Google Scholar
  61. Prapulla SG, Jacob Z, Chand N, Rajalakshmi D, Karanth NG (1992) Maximization of lipid production by Rhodoterula gracilis CFR-1 using the response surface methodology. Biotechnol Bioeng 40:965–970Google Scholar
  62. Primrose S, King D, Yaworski ED, Radhakrishnan J, He D, Xiao X (1997) Fermentative process for preparation of compactin. US Patent 561173Google Scholar
  63. Ramirez C (1982) Manual and atlas of the Penicillia. Elsevier, Amsterdam, pp 349–351Google Scholar
  64. Reynolds KA, Demain AL (1997) Rapamycin, FK506 and ascomycin related compounds. In: Strohl WR (ed) Biotechnology of Antibiotics, 2nd edn. Dekker, New York, p 497Google Scholar
  65. Roseiro JC, Esgalhado ME, Amaral Collaco MT, Emery AN (1992) Medium development for xanthan production. Process Biochem 27:167–175CrossRefGoogle Scholar
  66. Serizawa N, Nakagawa K, Hamano K, Tsujita Y, Terahara A, Kuwano H (1983a) Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530 B). J Antibiot 36:604–607PubMedGoogle Scholar
  67. Serizawa N, Nakagawa K, Tsujita Y, Terahara A, Kuwano H (1983b) 3-Hydroxy-ML-236B (3-hydroxy compactin), microbial transformation product of ML-236B (compactin). J Antibiot 36:608–610PubMedGoogle Scholar
  68. Serizawa N, Serizawa S, Nakagawa K, Furuya K, Okazaki T, Terahara A (1983c) Microbial hydroxylation of ML-236B (compactin), studies on microorganisms capable of 3α-hydroxylation of ML-236B. J Antibiot 36:887–891PubMedGoogle Scholar
  69. Serizawa N, Nakagawa K, Tsujita Y, Terahara A, Kuwano H (1983d) 6-hydroxy-iso-ML-236B and ML-236A, microbial transformation products of ML-236B. J Antibiot 36:918–920PubMedGoogle Scholar
  70. Sinensky M, Logel J (1983) Inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by mevinolin. J Biol Chem 258:8547–8549PubMedGoogle Scholar
  71. Smith JJ, Lilly MD, Fox RI (1990) The effect of agitation on the morphology and penicillin production of Penicillium chrysogenum. Biotechnol Bioeng 35:1011–1023Google Scholar
  72. Sugiyama M, Kodama T, Koniishi K, Abe K, Asami S, Oikawa S (2000) Compactin and Simvastatin, but not pravastatin, induces bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688–692CrossRefPubMedGoogle Scholar
  73. Sutherland A, Auclair K, Vederas (2001) Recent advances in the biosynthetic studies of lovastatin. Curr Opin Drug Discovery Dev 4:229–326Google Scholar
  74. Tanzawa K, Endo A (1979) Kinetic analysis of reaction catalyzed by rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase using two specific inhibitors. Eur J Biochem 98:195–210PubMedGoogle Scholar
  75. Tobert JA (1987) New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl coenzyme A reductase. Circulation 76:534–538PubMedGoogle Scholar
  76. Tony Lam YK, Gullo VP, Goeglman RT, Jorn D, Huang L, Deriso C, Monaghan RL, Putter I (1981) Dihydrocompactin, a new potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase from Penicillium citrinum. J Antibiot 34:614–616Google Scholar
  77. Vinci VA, Conder MJ, McAda PC, Phyllis C, Reeves CD, Rambosek J, Davis CR, Hendrickson LE (2001) DNA encoding triol polyketide synthase. US Patent 6 174 706Google Scholar
  78. Wächtershäuser A, Akoglu B, Stein J (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22:1061–1067CrossRefPubMedGoogle Scholar
  79. Wang YP, Chen YC, Chang W, Lin CL (2001) Mutant strain of Penicillium citrinum and use thereof for preparation of compactin. US Patent 6 323 021Google Scholar
  80. Wasser SP, Reshetnikov SV (2002) Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms. US Patent 6 372 462Google Scholar
  81. Yamashita H, Tsubokawa S, Endo A (1985) Microbial hydroxylation of compactin (ML-236B) and monacolin K. J Antibiot 38:605–609PubMedGoogle Scholar
  82. Ykema A, Lindsay JM (2000) Nitrogen feed in statin fermentation. US Patent 6 165 757Google Scholar
  83. Yuki A, Hosobuchi M, Yoshokawa H (2001) Penicillium citrinum genes associated with biosynthesis of ML-236B, precursor of 3-hydroxy-3-methylglutaryl CoA reductase inhibitor. World Patent 0112814Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Department of Biochemical Engineering and BiotechnologyIndian Institute of Technology-DelhiNew DelhiIndia
  2. 2.Department of Cell Biology, LRICleveland Clinic FoundationClevelandUSA

Personalised recommendations